Software As A Medical Device (SaMD) For Chronic Disease Management Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Software As A Medical Device (SaMD) For Chronic Disease Management Market Trends and Insights

Rising Chronic Disease Burden Amplified by Multi-Morbidity

Chronic disease remains the core demand driver for the Software as a Medical Device (SaMD) for Chronic Disease Management Market, as treatment increasingly requires long-duration monitoring, repeated intervention, and stronger patient follow-up. In the United States, chronic and mental health conditions account for 90% of annual healthcare spending, while more than 40.1 million Americans live with diabetes. Cardiovascular disease and stroke caused more than 850,000 deaths in 2024, and noncommunicable diseases cause more than 40 million deaths globally each year.^{[1]U.S. Food and Drug Administration, “Artificial Intelligence in Software as a Medical Device,” U.S. Food and Drug Administration, fda.gov} This demand favors software that tracks linked conditions across care settings, as patients often move across diabetes, cardiovascular, and metabolic pathways simultaneously.

AI-Enabled Continuous Risk Stratification and Personalization

AI is changing how the Software as a Medical Device (SaMD) for Chronic Disease Management Market creates value, as care teams can monitor risk continuously instead of relying on periodic readings. The FDA’s 2025 guidance work for AI and machine learning in medical software centered attention on life cycle management, post-clearance change control, and safer algorithm updates.^{[2]Centers for Disease Control and Prevention, “Fast Facts: Health and Economic Costs of Chronic Conditions,” Centers for Disease Control and Prevention, cdc.gov} Vendors with stronger change management plans can improve software faster without disrupting the regulatory pathway each time they refine a model. As a result, the market is moving toward platforms that combine algorithm performance with disciplined governance, larger data pools, stronger quality systems, and continuous validation.

Expansion of Value-Based Care and Outcome-Linked Reimbursement

Reimbursement change became one of the clearest commercial supports for the Software as a Medical Device (SaMD) for Chronic Disease Management Market in 2026. The CMS ACCESS model went live on July 5, 2026, and paid participating organizations based on measurable improvement in chronic conditions rather than service volume alone. This shift made SaMD tools more relevant because they can track outcomes, follow patients between visits, and document whether care teams meet defined care goals. The FDA TEMPO pilot, announced in December 2025, added another pathway for digital health devices tied to meaningful patient outcomes in chronic conditions.

Remote Patient Monitoring Integration With Connected Devices

Remote monitoring is becoming a routine part of chronic care delivery, giving the Software as a Medical Device (SaMD) for Chronic Disease Management Market a broader operating base. Dexcom presented results from the CONNECT randomized controlled trial in June 2026, showing statistically significant A1C reduction in people with Type 2 diabetes not using insulin who used Dexcom G7 compared with standard care. ResMed received FDA clearance in November 2025 for its AI-enabled Personalized Therapy Comfort Settings software, extending adaptive treatment support into the home setting. iRhythm reported that patients can self-apply home-based monitoring devices with strong compliance and data quality, supporting the shift away from clinic-only workflows.

Clinical Validation and Evidence Generation Bottlenecks

Clinical validation remains a significant restraint in the Software as a Medical Device (SaMD) for Chronic Disease Management Market, as evidence generation is slower and more expensive than standard software release cycles. The FDA’s AI-related SaMD work shows that developers must support safe change management and ongoing validation, not just initial clearance. Review timelines vary by device complexity, while quality systems, documentation controls, and software life cycle processes add fixed costs before companies can scale revenue. A 2026 framework called for good digital medicine practices and more consistent validation standards; however, until harmonization improves, evidence requirements will continue to favor better-funded companies.

Reimbursement Variability Across Therapies and Geographies

Reimbursement remains uneven across the Software as a Medical Device (SaMD) for Chronic Disease Management Market, although policy momentum has improved in the United States. CMS ACCESS has created a stronger route for outcome-linked adoption, but payment clarity remains inconsistent across regions and disease categories. As a result, developers must manage multiple commercial models, including provider contracting, employer sales, payer partnerships, and patient-paid use cases. This mismatch slows sales cycles, complicates product planning, and limits market scaling in lower-coverage regions, pushing vendors to prioritize applications with clearer reimbursement first.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Application: Diabetes SaMD Anchors Share While Cardiovascular Reshapes Growth

Diabetes Management held 39.55% of the application base in 2025, giving it the largest position within the Software as a Medical Device (SaMD) for Chronic Disease Management market share. The segment benefited from a mature connected care stack covering continuous glucose monitoring, dose support, and automated insulin delivery. Dexcom’s G7 15-Day Continuous Glucose Monitoring System received FDA clearance on February 3, 2026, underscoring continued product refinement. 

The diabetes application continued to expand as developers targeted more complex user groups beyond the broad insulin-treated population. WellDoc registered its Rx App for Diabetes in Pregnancy and Insulin Pump Users with the FDA in March 2026, indicating deeper specialization within the segment. Cardiovascular Disease Management is projected to record the fastest CAGR of 21.93% from 2026 to 2031, increasing the Software as a Medical Device (SaMD) for Chronic Disease Management market size as care models become more continuous and data-driven. 

By Deployment: Cloud Dominance Persists While Hybrid Models Gain Enterprise Preference

Cloud-Based deployment accounted for a 64.22% share in 2025, keeping it at the center of the Software as a Medical Device (SaMD) for Chronic Disease Management market size by deployment. The model supports broad patient access, large data storage requirements, and regular software improvements without site-by-site updates. Cloud architecture also aligns with longitudinal monitoring, where repeated data capture and ongoing clinical review create value.

The Hybrid model is forecast to expand at a 22.67% CAGR through 2031 as buyers seek cloud analytics with local control over sensitive health data. Hospitals and health systems want scalability, but they also need stronger control over patient data storage and movement. On-Premise setups remain relevant in high-security environments, public health systems, and facilities with slower cloud migration timelines. As a result, deployment strategy is becoming part of the clinical and operational buying decision, not only an IT choice.

By End User: Provider Workflows Hold Scale While Home Care Expands Fastest

Healthcare Providers held a 47.66% share in 2025, making them the largest end-user group across the Software as a Medical Device (SaMD) for Chronic Disease Management market. This position reflected the continued importance of hospital and clinic workflows, where clinicians rely on dashboards, alerts, and software-supported care planning. Provider adoption remains strongest when monitoring tools fit into existing decision routines and support follow-up for high-risk chronic patients.

Patients and Home Care Settings are projected to grow at a 23.35% CAGR through 2031, making this the fastest-moving end-user segment. iRhythm’s AVALON study showed that commercially insured patients who self-applied the Zio LTCM device at home had the highest diagnostic yield and the lowest likelihood of cardiovascular events compared with other ambulatory cardiac monitoring modalities. Employers are also using chronic disease software to manage absenteeism, productivity loss, and downstream claims costs. As more care moves into the home, the market gains a larger role in adherence, therapy adjustment, and patient engagement.

By Risk Class: Class II Leads the Current Base While Class III Lifts Future Complexity

Class II devices held a 52.33% share in 2025, placing them at the center of the Software as a Medical Device (SaMD) for Chronic Disease Management market share by risk class. This category has been commercially productive because it supports clinically meaningful monitoring and decision support without the heavier burden of the most complex approvals. The 510(k) pathway has enabled companies such as Dexcom, iRhythm, and ResMed to build product families with recurring improvements and new clinical use cases.

Class III devices are projected to grow at a 22.33% CAGR through 2031, indicating stronger demand for software that can influence higher-acuity treatment decisions. As developers move further into therapy adaptation and complex decision support, evidence requirements and surveillance needs increase. Class I software still supports engagement, symptom tracking, and self-management across the broader care journey. The mix across Class I, Class II, and Class III shows that the industry is moving from basic monitoring toward deeper clinical involvement.

Geography Analysis

North America is expected to hold 42.25% of the Software as a Medical Device (SaMD) for Chronic Disease Management market share in 2025, maintaining its lead among regional markets. The region benefits from stronger reimbursement channels, deeper insurance penetration, and a larger base of digital health developers than most other geographies. The CMS ACCESS model, scheduled to launch on July 5, 2026, is expected to create a direct policy signal that measurable improvements in chronic care can support payment. The FDA’s TEMPO pilot also adds momentum by outlining a pathway for technology-enabled patient outcomes in chronic conditions. Canada is also gaining relevance, as Huma Therapeutics received a Health Canada Class II Medical Device Licence for its cloud-based digital health platform in April 2025.

Europe remains the second-largest region in the user-supplied draft, supported by a regulated healthcare base and growing interest in reimbursable digital therapeutics. Germany stands out because it offers a clearer route for digital health reimbursement than most other European markets. This framework gives developers a more practical entry point for software commercialization in chronic care. However, the region continues to progress unevenly because payment conditions and adoption rates vary widely across national healthcare systems.

Asia-Pacific is projected to grow at a CAGR of 23.95% through 2031, making it the fastest-expanding regional opportunity and increasing the Software as a Medical Device (SaMD) for Chronic Disease Management market size during the forecast period. Large chronic disease populations, rising healthcare expenditure, and increasing digital health adoption across major economies support this growth. China and India offer the largest patient pools, especially across diabetes, cardiovascular disease, and respiratory conditions. Japan serves as an important near-term commercial marker, as iRhythm launched its Zio ECG Recording and Analysis System in the country in May 2025 through Senko Medical Instrument.